Ross McLeod has joined the Royal Australasian College of Surgeons (RACS) to contribute to a Health Technology Assessment (HTA) commissioned by the Swiss Federal Office of Public Health (FOPH).

 

This study evaluates the effectiveness, safety, cost-effectiveness, and budgetary impact of calcitonin gene-related peptide (CGRP) antagonists—specifically erenumab (Aimovig®), fremanezumab (Ajovy®), galcanezumab (Emgality®), and eptinezumab (Vyepti®)—in preventing episodic and chronic migraines.

 

The assessment aims to inform reimbursement decisions by comparing these novel therapies to standard preventive treatments